Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Total exit value breached the $10 billion mark for the first time to touch $10.3 billion this calendar, from $9.4 billion in 2015
The sentiment-driven rally also got support from stock specific earning results and Finance Minister Arun Jaitley's statement that the Centre will step up reforms to attract more investment and fill up infrastructure deficit.
.jpg)
The move is expected to delay the introduction of low-priced medicines in the market.
Hero MotoCorp's promoter Pawan Munjal emerged as the highest paid director.
An innovator creates intellectual property for a need no one knows exists, says Chandru Chawla.
Of the 30-share Sensex, 13 ended higher, while 17 led by Power Grid, Tata Steel, Bajaj Auto, Hero MotoCorp, NTPC, Tata Motors, Dr Reddy's, M&M, GAIL, Infosys and L&T finished lower, fell by up to 2.40 per cent
Dilip Shanghvi has never tried to be everything to everybody.
Benchmark indices plunge 4.7% in the first full week of 2016.
Analysts say those taking exposure through stocks could look at firms focused on domestic business
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
The 50-share NSE Nifty was trading lower by 24 points.
The BSE Midcap and Smallcap indices underperformed the largecaps and ended over 1% lower.
While the government's demonetisation move is aimed at curbing under-invoicing, the worry was that retailers would de-stock in the short term, impacting sales.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
.jpg)
The debt-equity ratio was as high as 1.4 times the net worth as certificates of deposit and inter-corporate deposits gained popularity.
Earning woes drag markets lower; TCS, HUL lead fall.
Dilip Shanghvi founded Sun Pharma in 1983.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
Asian markets were trading mixed with the Nikkei gaining after the US dollar strengthened against the yen.
The BSE benchmark index is yet to give any indication on the monthly Fibonacci charts.
The recovery was led by pharma majors led by Dr Reddy's Labs.
Indian loses chance to be research hub as domestic drug companies move R&D overseas.
The former McKinsey India head is presently on board of many big Indian conglomerates.
Geopolitical concerns, earnings sees investors rush to safe haven plays post the Union Budget presentation in July.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers's queries on stocks they own or want to buy.
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
The local markets are expected to react to global triggers until the government announces the Union Budget.
Instead of being carried away by Friday's historic election verdict, savvy investors were seen taking money off the table, after the benchmark Sensex rallied about 1,500 points in intra-day trade.
Of these, three stocks belong to the automobile pack and two are from the pharma.
Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.
Infosys, TCS, ICICI Bank and Sun Pharma among the top losers of the hour.
In peace and at war, firms remain tethered to promoter families in a uniquely Indian way.
India had been engaged in a contentious battle with the US over the issue, especially in the pharmaceutical sector.
Analysts now expect India Inc to report a decline in both top line and bottom line for the September quarter.
The latest price revision includes mostly cardiovascular drugs, anti-bacterials, anti-herpes, contraceptives and gastrointestinal medicines
Decline in the rupee coupled with a slide in the crude oil prices have dented the sentiments.
More than half the Sensex companies have declared their results for the third quarter and there are more positive surprises than disappointments.
Shree Cement beats ACC in market value, Lupin ahead of Dr Reddy's Labs
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances